Skip to main content
. 2012 Jan 31;8(3):149–155. doi: 10.1200/JOP.2011.000360

Figure 3.

Figure 3.

Estimated relative changes in the use of filgrastim/pegfilgrastim and myelosuppressive chemotherapy. The IMS Health Drug Distribution Database (1994-2008) and dosing data were used to calculate the number of days receiving filgrastim/pegfilgrastim on the basis of WHO-defined daily doses. The numbers of doses of chemotherapeutic agents were calculated by using recommended dosing data from the package inserts.